DE69121551D1 - Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff - Google Patents

Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Info

Publication number
DE69121551D1
DE69121551D1 DE69121551T DE69121551T DE69121551D1 DE 69121551 D1 DE69121551 D1 DE 69121551D1 DE 69121551 T DE69121551 T DE 69121551T DE 69121551 T DE69121551 T DE 69121551T DE 69121551 D1 DE69121551 D1 DE 69121551D1
Authority
DE
Germany
Prior art keywords
antineoplastic
antineoplastic effect
potentiating
effect
strengthening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69121551T
Other languages
English (en)
Other versions
DE69121551T2 (de
Inventor
Junji Uchida
Hiroyuki Okabe
Teiji Takechi
Setsuo Takeda
Yuji Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17034249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69121551(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of DE69121551D1 publication Critical patent/DE69121551D1/de
Application granted granted Critical
Publication of DE69121551T2 publication Critical patent/DE69121551T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
DE69121551T 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff Expired - Lifetime DE69121551T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23871990 1990-09-07
PCT/JP1991/001187 WO1992004028A1 (fr) 1990-09-07 1991-09-05 Potentialisateur d'effets antineoplasique et agent antineoplasique

Publications (2)

Publication Number Publication Date
DE69121551D1 true DE69121551D1 (de) 1996-09-26
DE69121551T2 DE69121551T2 (de) 1997-01-02

Family

ID=17034249

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69121551T Expired - Lifetime DE69121551T2 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
DE10299023C Active DE10299023I2 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE10299023C Active DE10299023I2 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Country Status (14)

Country Link
EP (1) EP0500953B1 (de)
JP (1) JP2557303B2 (de)
KR (1) KR0146952B1 (de)
AT (1) ATE141506T1 (de)
AU (1) AU644684B2 (de)
CA (1) CA2071819A1 (de)
DE (2) DE69121551T2 (de)
DK (1) DK0500953T3 (de)
ES (1) ES2091941T3 (de)
GR (1) GR3021003T3 (de)
HU (1) HU211739A9 (de)
LU (1) LU90791I2 (de)
NL (1) NL300041I2 (de)
WO (1) WO1992004028A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310573A (ja) * 1992-05-01 1993-11-22 Dotsuto:Kk リウマチ治療薬
US5643191A (en) * 1995-01-26 1997-07-01 Sorin Biomedical Inc. Cardioplegia delivery system and method for converting from warm cardioplegia to cold cardioplegia
US5702358A (en) * 1995-02-23 1997-12-30 Sorin Biomedical Inc. Cardioplegia delivery apparatus and method of use
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
NZ542150A (en) 2003-03-14 2009-09-25 Taiho Pharmaceutical Co Ltd Antitumor effect potentiator and antitumor agent
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
KR102258514B1 (ko) * 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5953885B2 (ja) * 1978-02-10 1984-12-27 大鵬薬品工業株式会社 抗腫瘍剤組成物
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
JPS5780319A (en) * 1980-11-06 1982-05-19 Taiho Yakuhin Kogyo Kk Anti-tumor agent having reduced toxicity
JPS5838210A (ja) * 1981-08-31 1983-03-05 Taiho Yakuhin Kogyo Kk 直腸投与用製剤

Also Published As

Publication number Publication date
ATE141506T1 (de) 1996-09-15
NL300041I1 (nl) 2001-06-01
CA2071819A1 (en) 1992-03-08
EP0500953A1 (de) 1992-09-02
AU8447991A (en) 1992-03-30
GR3021003T3 (en) 1996-12-31
DE69121551T2 (de) 1997-01-02
KR0146952B1 (ko) 1998-08-17
WO1992004028A1 (fr) 1992-03-19
KR927002224A (ko) 1992-09-03
EP0500953A4 (en) 1993-04-21
DE10299023I2 (de) 2010-05-06
EP0500953B1 (de) 1996-08-21
JP2557303B2 (ja) 1996-11-27
LU90791I2 (fr) 2001-10-08
DK0500953T3 (da) 1997-01-06
HU211739A9 (en) 1995-12-28
ES2091941T3 (es) 1996-11-16
AU644684B2 (en) 1993-12-16
NL300041I2 (nl) 2002-02-01
DE10299023I1 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
MX9707453A (es) Derivados de quinazolina.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
IL119207A0 (en) Treatment of tinnitus using neuroprotective agents
ATE173627T1 (de) Medizinische zusammensetzung
DE69121551D1 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
BG100599A (en) Antiviral form and therapeutical method
MY104521A (en) Treatment of depression.
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
NO923198L (no) Terapeutiske midler
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
KR890007737A (ko) 진토작용을 하는 약제
DE69228945D1 (de) Pharmazeutische pentapeptid-zusammensetzung und ihre verwendung
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: TEGAFUR, URACIL UND CALCIUMFOLINAT; REGISTRATION NO/DATE: 51670.00.00, 20020122

Spc suppl protection certif: 102 99 023

Filing date: 20020617

V472 Withdrawal of application for spc

Free format text: PRODUCT NAME: TEGAFUR, URACIL UND CALCIUMFOLINAT; REGISTRATION NO/DATE: 51670.00.00, 20020122

Spc suppl protection certif: 102 99 023

Filing date: 20020617